Aa
Aa
A
A
A
Close
Avatar universal

nicotinamide inhibits hepatitis B virus replication in vitro and in vivo.

https://www.ncbi.nlm.nih.gov/pubmed/26660162

The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo.
Li WY1, Ren JH1, Tao NN1, Ran LK1, Chen X1, Zhou HZ1, Liu B1, Li XS1, Huang AL1, Chen J2.
Author information

1
    The Second Affiliated Hospital and The Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China.
2
    The Second Affiliated Hospital and The Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China. yixin_xinyuan***@****.

Abstract

We previously reported that SIRT1, an NAD(+)-dependent deacetylase belonging to the class III histone deacetylases, enhances hepatitis virus B (HBV) replication by targeting the transcription factor AP-1. However, the potential antiviral effects of nicotinamide, a SIRT1 inhibitor, have not yet been explored. In this study, we show that nicotinamide exhibits potent anti-HBV activity with little cytotoxicity. Nicotinamide suppressed both HBV DNA replicative intermediates and 3.5-kb mRNA expression. Moreover, nicotinamide treatment also suppressed core protein expression and the secretion of the hepatitis B surface antigen (HBsAg) and the hepatitis B e antigen (HBeAg) in HBV-expressing cell models. Importantly, nicotinamide treatment suppressed serum HBV DNA, HBsAg and HBeAg levels and liver HBV DNA in HBV-transgenic mice. Furthermore, using a dual-luciferase reporter assay, it was found that nicotinamide exhibited a marked inhibitory effect on the HBV core, SpI, SpII and X promoters, accompanied by decreased expression of the transcription factors AP-1, C/EBPα and PPARα. Therefore, nicotinamide suppresses HBV replication in vitro and in vivo by diminishing HBV promoter activity. This study highlights the potential application of nicotinamide in HBV therapy.
3 Responses
Avatar universal
https://www.ebiomedicine.com/article/S2352-3964(19)30686-3/pdf

Niacin analogue,6Aminonicotinamide,a novel inhibitor of hepatitisB virus replication and HBsAgproduction
Avatar universal
it would be good to get hbsag quant test, then try 3g of nicotinamide daily for few months (checking ast/alt every month for safety) and see if it has any effect on hbsag quant
6Aminonicotinamide should be better but i didn t find cheap sources for this
Avatar universal
I took tons of nicotinamide one time, trying this. My HBSAG went higher than ever and I felt absolutely awful. I then read some more studies that make it sound like it tends to increase the viral load for secondary reasons. I do not recommend this experience at all.
2 Comments
Ohh that's unexpected
if hbsag is not low after years of nucs or pegintf i dont think you can have any results from most substances and drugs available today.this should be checked by someone on nucs many years and hbsag less or equal to 1000iu/ml.also note that hbsag increses before going down even on pegintf and new drugs on trials that lower hbsag irrespective of hbvdna levels.this is not to say nicotinamide works or not, but to remember all memebers that you must have some immune system activity (rescued tcells by years of nucs and low hbsag) to try such weak substances and see if any effect can be achieved
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
Chlamydia, an STI, often has no symptoms, but must be treated.
For people with Obsessive-Compulsive Disorder (OCD), the COVID-19 pandemic can be particularly challenging.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.